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Are Men Who Undergo Radical Prostatectomy with Lower Urinary 
Tract Symptoms at an Increased Risk for Aggressive Prostate 
Cancer? 
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Department of Urology, Gangnam Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea
Purpose: We aimed to determine whether prediagnostic lower urinary tract symptoms 
(LUTS) are associated with the aggressiveness of nonmetastatic prostate cancer (PCa) 
and compared the clinicopathologic features of PCa patients with and without preexist-
ing LUTS.
Materials and Methods: We retrospectively reviewed the medical records of 295 pros-
tate cancer patients who underwent a radical prostatectomy (RP) by a single surgeon 
from 2006 to 2010. A total of 205 patients were assigned to two groups according to 
whether they showed preoperative LUTS (International Prostate Symptom Score 
[IPSS]≥8). Clinical, operative, pathologic, and postoperative functional data were 
collected.
Results: The mean age at RP was 62.7 years in the no LUTS group (group A, n=108) 
and 64.7 in the LUTS group (group B, n=97). The baseline mean IPSS score was 6.1 
in group A and 14.6 in group B (p=0.029). The incidence of pathologic T3a stage or above 
was significantly higher in group B than in group A (p=0.036). The mean postoperative 
follow-up period was 16.8 months (range, 4 to 38 months). The mean time to biochemical 
recurrence was 16.9 and 18.2 months in groups A and B, respectively (p=0.148). The 
median time to recovery of urinary incontinence was 3.6 and 3.3 months in groups A 
and B, respectively. 
Conclusions: PCa patients without baseline LUTS had a favorable result of pathologic 
T stage even though there were no significant differences in biochemical recurrence 
or recovery of postoperative incontinence compared with patients with baseline LUTS.
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INTRODUCTION
Generally, serum prostate-specific antigen (PSA) testing 
in clinical practice is used either in the screening of asymp-
tomatic men or in the workup of men with lower urinary 
tract symptoms (LUTS). Although an elevated PSA level 
can be an important predictor of prostate cancer (PCa), it 
may also be indicative of benign prostatic hyperplasia. 
Several studies have reported a weak association between 
LUTS and the detection of PCa [1,2]. Men with LUTS are 
often concerned that their symptoms indicate PCa [3]. 
They believe the PSA evaluation to be more effective for the 
detection of PCa than do men who have not been tested [4]. 
PSA, Gleason score at biopsy, and clinical stage are cur-
rently the most reliable markers of aggressiveness or prog-
nosis for PCa [3]. However, controversy exists regarding 
whether prediagnostic LUTS affects the aggressiveness of 
PCa [1,5]. Collin et al reported that associations of LUTS 
with PCa did not differ between localized or advanced PCa 
[1]. In our study, we aimed to determine whether pre-
diagnostic LUTS are associated with the aggressiveness of 
nonmetastatic PCa and compared the clinicopathologic Korean J Urol 2011;52:819-823
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features of PCa patients with and without preexisting 
LUTS.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 295 
prostate cancer patients who underwent a radical prosta-
tectomy (RP) by a single surgeon from 2006 to 2010. In our 
study, prostate cancer diagnosis took one of the following 
two main routes: asymptomatic diagnosis following a 
screening test or symptomatic diagnosis with LUTS. All 
patients attended the center’s urology department at the 
initial visit for completion of an International Prostate 
Symptom Score (IPSS) questionnaire, digital rectal exami-
nation, PSA test, and transrectal ultrasound (TRUS) (12 
cores). We defined the LUTS group as those with IPSS ≥8 
and the no LUTS group as those with IPSS ＜8. 
After excluding those patients with unclear medical re-
cords, a history of medication with an alpha blocker or 5 al-
pha reductase inhibitor, a history of prostate surgery, clin-
ically insignificant PCa according to the Epstein criteria, 
or a history of prostatitis, 205 patients were assigned to two 
groups according to the presence or absence of preoperative 
LUTS: group A (no LUTS, IPSS＜8) and group B (LUTS, 
IPSS≥8) [6]. Clinical, operative, pathologic, and postope-
rative functional data were collected. Biochemical re-
currence was defined as three consecutive rises in the PSA 
level, each ＞3 months apart, with a final value greater 
than 1.0 ng/ml [7,8]. Postoperative continence was defined 
as being pad-free.
1. Biopsy protocol 
A kit from BK Medical (Herlev, Denmark), was used for 
TRUS, and an automatic gun was used for 12 prostatic biop-
sies (right 6 cores and left 6 cores). The 12 core biopsies were 
done in each patient by an urologist with 12 years of 
experience. The 12 core biopsy regimen was performed ac-
cording to a previously established standard biopsy proto-
col [9]. The standard length of the biopsy cores was 15 mm 
and each core was embedded separately and submitted in 
multiple containers.
2. Pathology
Pathological grading was done by the Gleason scoring sys-
tem, and pathologic review was performed by a single expe-
rienced urologic pathologist (SWH). The prostatectomy 
specimens were fixed overnight (10% neutral buffered 
formaldehyde) and coated with India ink. Transverse 
whole-mount step-section specimens were obtained at 4 
mm intervals on a plane. The presence and extent of cancer 
were outlined on the glass cover. The presence of tumor 
cells beyond the capsular margin was defined as ex-
tracapsular extension. 
3. Statistics
Statistical analyses were performed by using a Student’s 
t-test to evaluate the demographic and clinical differences 
between the LUTS and no LUTS groups. A Pearson’s 
chi-squared test was used to compare groups for categorical 
variables. The Kaplan-Meier method was used to compare 
the duration of continence recovery and the biochemical re-
currence rate. The log rank test analyzed the difference be-
tween the two groups, and a p-value of ＜0.05 was consid-
ered significant. All data were analyzed by using SPSS ver. 
12.0 (SPSS Inc., Chicago, IL, USA). Statistical analysis was 
performed with the Graphpad Prism ver. 5.00 (Graphpad 
Instat, San Diego, CA, USA).
RESULTS 
The mean age at RP was 62.7 years in the no LUTS group 
(group A, n=108) and 64.7 years in the LUTS group (group 
B, n=97). Other preoperative baseline parameters such as 
past history, body mass index, and clinical stage were not 
statistically different between the two groups. The base-
line mean IPSS score was 6.1 in group A and 14.6 in group 
B (p=0.029), and the mean quality of life score was 2.6 in 
group A and 4.2 in group B (p=0.013). There was no sig-
nificant difference in preoperative prostate-specific anti-
gen levels (10.1 vs. 11.2 ng/ml in groups A and B, respec-
tively) (Table 1). The prostate volume was large in the 
LUTS group (39.8 cc) compared with the no LUTS group 
(34.5 cc); however, there was no significant difference be-
tween the two groups. 
The incidence of a pathologic stage of T3a or above was 
significantly higher in group B than in group A (p=0.036). 
After RP, the incidence of Gleason scores of 7 or more was 
69 (64.8%) and 59 (60.9%) in groups A and B, respectively. 
The incidence of a positive surgical margin showed no sig-
nificant difference between the two groups (Table 2). In the 
multivariate analysis, IPSS total scores and biopsy 
Gleason scores were predictable values for locally ad-
vanced PCa (Table 3). 
The mean postoperative follow-up period was 16.8 
months (range, 4 to 38 months) (Table 2). We used the 
Kaplan-Meier analysis to compare the biochemical re-
currence rate between the two groups (Fig. 1). The mean 
time to biochemical recurrence was 16.9 and 18.2 months 
in groups A and B, respectively (p=0.148). The median time 
to recovery of urinary incontinence was 3.6 and 3.3 months 
in groups A and B, respectively. This result did not differ 
significantly between the two groups. 
DISCUSSION
In the present study, more than half (52.7%) of the men with 
no baseline LUTS were diagnosed with PCa and under-
went RP. In addition, we demonstrated that the group with 
no LUTS at baseline had a favorable pathologic stage (≤
T2) of PCa after RP compared with the LUTS group, even 
though this result did not affect the biochemical recurrence 
rate. However, there was no evidence of a positive associa-
tion with advanced PCa, which was partially contradictory 
to our results. Because most PCa develops in the peripheral Korean J Urol 2011;52:819-823
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TABLE 1. Preoperative clinical tumor characteristics of prostate cancer patients
Variables  No LUTS group (n=108) LUTS group (n=97) p-value
Mean age (yr)
Prostate volume (cc)
Preoperative PSA (nl/ml)
a
IPSS total score (mean)
a
QoL scores (mean)
a
Bx Gleason sum (mean)
a,b
    ≤6 (%)
    7 (%)
    ≥8 (%)
Clinical T stage (N)
b
    ≤T2c (%)
    ≥T3 (%)
  62.7±5.3 (49-71)
  34.5±2.9 (16-52)
      10.1±0.8 (3.5-19.8)
6.1±0.5 (0-7)
2.6±0.2 (0-4)
3 (2.8)
31 (28.7)
74 (68.5)
76 (70.4)
32 (29.6)
  64.7±4.9 (51-74)
  39.8±3.2 (19-79)
      11.2±0.9 (3.1-21.7)
14.6±1.2 (9-35)
4.2±0.3 (2-6)
6 (6.2)
36 (37.1)
55 (56.7)
63 (64.9)
34 (35.1)
0.314
0.085
0.612
0.029
0.013
0.222
0.192
The values in parentheses for age, prostate volume, preoperative PSA, and PSA density are ranges, LUTS: lower urinary tract symptoms, 
PSA: prostate-specific antigen, IPSS: international prostate symptom score, QoL: quality of life, 
a: student’s t-test, 
b: pearson chi-square 
test
TABLE 2. Pathological findings from analyses of prostatectomy 
specimens according to preoperative LUTS 
No LUTS group 
(n=108)
LUTS group 
(n=97)
p-value
Postoperative 
Gleason score
    ≤6 (%)
    7 (%)
    ≥8 (%)
Postoperative 
pathologic stage (%)
    T1-T2 (%)
    ≥T3 (%)
Positive surgical 
margins (N)
Biochemical 
recurrence rate
    No (%)
    Yes (%)
Mean duration to 
biochemical recur-
rence (mo)
b
39 (36.1)
60 (55.5)
9 (8.3)
82 (75.9)
26 (24.1)
16 (14.8)
87 (80.6)
21 (19.4)
16.9±1.5 (6-36)
33 (34.0)
45 (46.4)
14 (14.5)
59 (60.8)
38 (39.2)
13 (13.4)
79 (81.4)
18 (18.6)
17.2±1.6 (8-48) 
p=0.193
a
p=0.036
a
p=0.151
a
p=0.104
a
p=0.158
LUTS: lower urinary tract symptoms, 
a: pearson chi-square test, 
b: student’s t-test
TABLE 3. The results of the multiple logistic regression analysis 
of predictive factors for locally advanced prostate cancer 
(pathologic stage T3 or above)
Variable Odds ratio (95% CI) p-value
Age (yr)
IPSS total score 
QoL scores 
PSA
Biopsy Gleason sum
    Gleason scores ≤6
    Gleason scores ＞6
% of positive cores in a biopsy
No. of positive cores
Prostate volume
Clinical T stage
    ≤T2
    ≥T3
1.234 (0.843-3.117)
1.757 (0.722-3.138)
1.025 (0.253-1.946)
1.293 (0.932-1.354)
Reference
1.952 (0.959-2.819)
0.882 (0.501-1.421)
1.091 (0.091-2.312)
1.141 (0.735-1.559)
Reference
1.312 (0.482-1.912)
0.581
0.037
0.512
0.367
0.025
0.355
0.418
0.329
0.182
CI: confidence interval, IPSS: international prostate symptom 
score, QoL: quality of life, PSA: prostate-specific antigen.
zone of the prostate and needs to be advanced before pro-
voking LUTS, a positive association with advanced cancer 
would be expected if such cancers truly caused LUTS. Our 
results indicate that the prospect of benefit outweighs the 
potential for harm and that screening for early PCa is 
worthwhile even though the value of population-based 
screening has to be demonstrated in well-conducted 
randomized trials. 
There is a widespread misconception that the risk of PCa 
is increased with the severity of LUTS, but a lack of cancer 
symptoms does not mean that there is no cancer. Catalona 
et al found that the absence of prostatic disease symptoms 
is more predictive of cancer than their presence [10]. In ad-
dition, there are many reports that patients with baseline 
LUTS are not at higher risk for PCa than are asymptomatic 
men [1,8,11]. Especially, men with a PSA level of ≥3 ng/ml 
and LUTS were more likely to be diagnosed with benign dis-
ease than with PCa [1]. However, the present study in-
cluded only patients treated with RP, and the data there-
fore give no information about patients referred to the de-
partment with or without symptoms who did not have a di-
agnosis of PCa or any nonsurgical treatment thereof. Our 
results warrant future study to determine the “pure” in-
cidence of prostate cancer in the screened population of 
Korea. 
In the present study, there were no significant differ-
ences in postoperative Gleason scores, biochemical re-
currence, or positive surgical margins, regardless of the Korean J Urol 2011;52:819-823
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FIG. 1. Kaplan-Meier analysis of time to biochemical recurrence (A) and recovery of continence (B) for patients with and without 
baseline lower urinary tract symptoms. BCR: biochemical recurrence, IPSS: international prostate symptom score.
presence or absence of baseline LUTS. This finding is im-
portant, because measurement of PSA when a patient has 
LUTS is controversial. Regardless of the PCa detection rate 
according to baseline LUTS, our results suggest that there 
might be more aggressive pathologic features in the no 
LUTS group if the subjects had not participated in PCa 
screening. Some authors insist that PSA testing in men 
with LUTS should be standard procedure, whereas others 
believe it is the equivalent of screening and therefore in-
appropriate [12,13]. The incidence of PCa has rapidly in-
creased over the past 10 years in East Asia, including Korea 
[14,15]. In South Korea, PSA screening is not yet recom-
mended in the national early detection strategy for cancer, 
even though a growing proportion of patients undergoing 
RP are asymptomatic and are diagnosed as a result of un-
systematic PSA screening. In a 2004 telephone survey of 
over 700 Korean men older than 50 years in a small city, 
approximately 15% had been screened for PCa during the 
previous 2 years (unpublished data), a much lower rate 
than the 75% reported for men in the United States [16]. 
In view of the growing proportion of asymptomatic PCa, we 
suggest that PSA screening is needed not only in men with 
LUTS that could be caused by PCa, but also in men who are 
asymptomatic at baseline [17,18]. 
There are several limitations to our study. First, the 
short duration with a relatively small number of patients 
requires further investigation for a longer period of time 
with a larger number of patients. In fact, we could not ex-
plain the exact background by which the correlation be-
tween low IPSS and low T stage was made. We think this 
will be an important point to clarify in future studies. Also, 
we were unable to include advanced or metastatic PCa cas-
es because only RP patients were included in our study. 
Therefore, this study cannot assess the relationship be-
tween LUTS and more advanced or metastatic PCa. 
CONCLUSIONS
PCa patients without baseline LUTS had a favorable result 
of pathologic T stage even though there were no significant 
differences in biochemical recurrence or recovery of post-
operative incontinence compared with patients with base-
line LUTS.
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